EVENTS:   Best Equity Short Ideas Conference Call 12 - Zach Shannon/Corto Capital Advisors & Craig Huber/Huber Research Partners & Thomas Beevers /Forensic Alpha & Ed Steele/Iron Blue Financials & Bill Campbell/Paragon Intel - 12 Nov 25   Will AI Deflate the World? Macro Lessons from Three Industrial Revolutions and China - Manoj Pradhan/Talking Heads Macro - 13 Nov 25     ROADSHOWS: Forest Products Sector Equity and Commodity Research With Expertise in Distressed Debt - Kevin Mason /ERA Research   •   London   12 - 14 Nov 25       Buyside to Buyside Forum and Expert Calls across TMT, Consumer, Healthcare and Fintech - Andrew Peters /Revelare Partners   •   London   17 - 19 Nov 25       Fundamental US Healthcare Short Ideas - Dr Elliot Favus /Favus Institutional Research   •   London   17 - 19 Nov 25      

Fortnightly Publication Highlighting Latest Insights From IRF Providers

Company Research

Market moving legal disputes…

MDC Financial Research

MDC's “Event-Driven Legal℠" Weekly Report summarises near-term legal events including analysis on their potential as share-price catalysts for the indicated companies. Recent coverage includes:

Arbutus Biopharma and Genevant Sciences recently filed Patent Infringement Lawsuit against Moderna seeking licensing fees for the manufacture and sale of Moderna’s vaccine for COVID-19.

IDT Corporation's Defense of a shareholder lawsuit challenging the repurchase of an Indemnification Claim from Straight Path Communications that spared it from having to pay $614m in FCC fines.

Sonos and Alphabet's continuing battles at the US International Trade Commission and US District Courts.

Edition: 130

- 04 March, 2022


Arbutus Biopharma (ABUS)

Healthcare

MDC Financial Research

ABUS should experience high volatility when the US Court of Appeals for the Federal Circuit issues its Decisions in Appellate Case Numbers: 20-1184 & 20-2329. Although Decisions may still be a few months away, these Patents relate to a Nucleic Acid delivery system comprising of a composite of multiple lipids. This delivery system appears to have ranges that overlap with Moderna's recent Covid-19 Vaccine; and therefore, ABUS may have grounds for an eventual Patent Infringement lawsuit.

Edition: 123

- 12 November, 2021